A2 Biotherapeutics, Inc.

A2 Biotherapeutics is a clinical-stage biotech company revolutionizing the treatment of solid tumors with its innovative Tmod™ cell therapy platform. Their unique approach utilizes a dual-receptor design, targeting tumor cells with an activator while simultaneously protecting normal cells with a blocker. This logic-gated system, combined with their proprietary Tmod™ technology, offers a powerful and precise way to selectively kill tumor cells, addressing the fundamental challenge of on-target, off-tumor toxicity. A2 Bio has two autologous Tmod™ CAR T therapies in clinical trials, targeting CEA (A2B530) and mesothelin (A2B694). These programs are driven by a robust preclinical data package and are being investigated in patients with a range of solid tumors.

Driven by a dedicated and experienced team, A2 Bio leverages its expertise in discovery, development, and manufacturing to build a robust pipeline of both autologous and allogeneic cell products. Their in-house cGMP manufacturing capabilities ensure efficient production and the advancement of their novel Tmod™ platform. A2 Bio is well-positioned to deliver a broad pipeline of T cell therapies to cancer patients, making a significant impact in the fight against cancer.

A2 Biotherapeutics offers flexible work arrangements as a benefit to its employees. They are committed to providing a supportive environment for their team members, including options for flexible work schedules and arrangements to help balance work and personal life. The company also provides a monthly flexible working allowance, which can be used for various needs, further enhancing the flexibility and work-life balance for employees.

A2 Biotherapeutics offers a comprehensive benefits package designed to support the well-being of its employees and their families. These benefits include health and wellness programs like medical, dental, and vision coverage, paid parental leave, life and disability insurance, as well as on-site snacks. Financial well-being is also addressed with competitive base salaries, bonus opportunities, equity participation, a 401K plan, and monthly flexible working allowances. The company also prioritizes lifelong learning with a Leadership Development Program, cutting-edge scientific training, and opportunities to publish research.

A2 Biotherapeutics is a clinical-stage biotech company dedicated to developing first-in-class logic-gated cell therapies to address the high unmet need in cancer. Their proprietary Tmod™ platform aims to revolutionize the treatment of solid tumors by targeting the loss of genetic material in tumors, enabling the selective destruction of cancer cells while sparing normal cells. Their focus is on developing both autologous and allogeneic cell products, with in-house cGMP manufacturing capabilities.

A2 Biotherapeutics promotes a collaborative, innovative, and impactful culture, emphasizing teamwork, accountability, and a commitment to delivering results. They value a diverse and inclusive community where individuals can thrive and contribute their best work, offering opportunities for professional development and leadership growth through their Leadership Development Program.

A2 Biotherapeutics is committed to fostering a vibrant and inclusive work environment where diverse minds can come together to do their best work. They believe in developing their people and are passionate about growing leadership from within, as evidenced by their Leadership Development Program (LDP). They are also committed to equal opportunity employment practices, ensuring all qualified applicants are considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.